Clinical, Pathological, and Prognostic Features of Male Breast Cancer: A Multicenter Study.
adjuvant endocrine therapy
breast cancer surgery
breast cancer survival
male breast cancer
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
11 Nov 2023
11 Nov 2023
Historique:
received:
22
08
2023
revised:
05
11
2023
accepted:
08
11
2023
medline:
27
11
2023
pubmed:
24
11
2023
entrez:
24
11
2023
Statut:
epublish
Résumé
Male breast cancer (BC) represents less than 1% of male tumors. Little is known about male BC characteristics, management, and survival, with many studies based on a small number of cases. Consequently, the treatment of male BC lacks specific guidelines. The aims of the study are to compare male and female breast cancer (FBC) in terms of cancer clinical and anatomopathological features and treatment approach, and to identify differences between male BC and FBC in terms of survival. Patients and methods: Data from 2006 to 2018 were retrospectively acquired. Amounts of 49 males and 680 postmenopausal females with primary non-metastatic BC who underwent breast surgery at Mauriziano Hospital or IRCCS Candiolo (TO-Italy) were included. The mean age at diagnosis for male BC was 68.6 years, and males presented a smaller tumor size than women (
Identifiants
pubmed: 37999136
pii: curroncol30110716
doi: 10.3390/curroncol30110716
pmc: PMC10670254
doi:
Substances chimiques
Tamoxifen
094ZI81Y45
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9860-9871Références
Oncologist. 2015 Jun;20(6):586-92
pubmed: 25948676
Endocr Relat Cancer. 2017 Mar;24(3):R27-R34
pubmed: 28062545
BMC Med. 2015 Jun 04;13:134
pubmed: 26044503
Breast Cancer Res Treat. 2018 Dec;172(3):539-544
pubmed: 30187168
Breast Cancer Res Treat. 2019 Jan;173(1):37-48
pubmed: 30267249
Int J Clin Oncol. 2014 Apr;19(2):280-7
pubmed: 23640121
Sci Rep. 2022 Jan 7;12(1):220
pubmed: 34997151
J Clin Oncol. 2008 May 10;26(14):2373-8
pubmed: 18413639
BMC Cancer. 2011 Aug 04;11:335
pubmed: 21816051
Clin Breast Cancer. 2018 Oct;18(5):e997-e1002
pubmed: 30007834
J Clin Oncol. 2010 Jun 1;28(16):2784-95
pubmed: 20404251
Cancer Treat Rev. 2019 Mar;74:29-34
pubmed: 30708267
Ann Surg Oncol. 2012 Oct;19(10):3199-204
pubmed: 22766989
Ann Epidemiol. 2005 Nov;15(10):773-80
pubmed: 16257362
Cancers (Basel). 2022 Jun 28;14(13):
pubmed: 35804947
Sci Rep. 2017 Mar 28;7:45293
pubmed: 28350011
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
J Clin Oncol. 2010 Apr 20;28(12):2114-22
pubmed: 20308661
Cancer Metastasis Rev. 2018 Dec;37(4):599-614
pubmed: 30232577
PLoS One. 2018 Apr 19;13(4):e0195572
pubmed: 29672549
Curr Oncol. 2023 Jan 21;30(2):1461-1472
pubmed: 36826073
Jpn J Clin Oncol. 2013 Oct;43(10):954-63
pubmed: 23935206
Breast Cancer Res. 2016 Feb 09;18(1):15
pubmed: 26857456
Crit Rev Oncol Hematol. 2017 May;113:283-291
pubmed: 28427518
J Clin Oncol. 2011 Nov 20;29(33):4381-6
pubmed: 21969512
Breast Care (Basel). 2013 May;8(2):102-9
pubmed: 24000280
Breast Care (Basel). 2011;6(2):136-141
pubmed: 21633630
Eur J Pharmacol. 2013 Oct 5;717(1-3):71-83
pubmed: 23545364
Clin Breast Cancer. 2013 Oct;13(5):309-14
pubmed: 23845572
Cancer. 2005 Dec 1;104(11):2359-64
pubmed: 16270318
Arch Surg. 2004 Oct;139(10):1079-82
pubmed: 15492147
Crit Rev Oncol Hematol. 2010 Mar;73(3):246-54
pubmed: 19442535
Ann Oncol. 2017 Aug 1;28(8):1700-1712
pubmed: 28838210
Int J Surg Case Rep. 2016;20S:8-11
pubmed: 26994487
Int J Biochem Cell Biol. 2014 Aug;53:526-35
pubmed: 24842109
J Breast Health. 2016 Oct 1;12(4):165-170
pubmed: 28331756
J Clin Oncol. 2007 Jan 1;25(1):118-45
pubmed: 17159189
Breast Cancer. 2021 Sep;28(5):1131-1140
pubmed: 33939116
Breast Cancer. 2020 Jul;27(4):724-731
pubmed: 32114665
Sci Rep. 2021 Jun 2;11(1):11639
pubmed: 34079019
Ann Surg Oncol. 2009 Apr;16(4):972-8
pubmed: 19184227